Business Wire

MN-ALPEGA

13.10.2020 16:17:08 CEST | Business Wire | Press release

Share
Alpega Partners with FourKites to Deliver Supply Chain Visibility in North America, Europe and Latin America

Alpega, a global provider of cloud-based transportation management systems (TMS), today announced it has partnered with FourKites, a global leader in real-time and predictive supply chain visibility for shippers, carriers and logistics service providers, as part of its strategic value-adding partner ecosystem.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005635/en/

The partnership delivers integrated real-time, in-transit freight tracking across all modes and serves Alpega customers of all industries and verticals, enabling improved visibility and reduced supply chain costs.

“Successful end-to-end supply chain planning and execution requires real-time visibility and dependable predictive ETAs,” said Matt Elenjickal, CEO at FourKites. “Our predictive visibility platform leverages machine learning and advanced analytics to provide supply chain professionals with the real-time data needed to make informed, trusted decisions, and to remain agile in the face of any circumstance.”

The partnership combines the modular, scalable transportation management solution, Alpega TMS, with FourKites’ global, multimodal real-time transportation visibility platform. With the largest integrated carrier-base, this integration gives Alpega customers enhanced live shipment tracking and visibility data directly linked to the transportation order in Alpega TMS, providing actionable insights to drive operational efficiencies across supply chain operations.

“Our strategy when it comes to partnerships, is to work with the best to complement our TMS product portfolio,” said Todd DeLaughter, CEO at Alpega Group. “Our partnership with FourKites will provide our customers globally with the critical transportation technology and valuable timely data they need to create a competitive advantage. We look forward to the opportunities this strategic relationship will provide our joint customer base.”

Alpega TMS brings transparency and efficiency to all trading partners across the supply chain through one shared data set and collaborative platform for managing all transportation workflows. Moreover, through its partnership with FourKites, Alpega TMS provides enhanced supply chain visibility across all transportation modes within logistics networks.

Customers can benefit from the Alpega TMS collaborative platform for managing the end-to-end transportation process – from sourcing through settlement – across simple to complex logistics networks; while FourKites provides the end-to-end, real-time predictive visibility and analytics for improved customer service and delivery exception management.

Having pioneered the application of predictive visibility to various aspects of supply chain operations, FourKites’ network now includes more than 400 of the world’s top shippers and their broker and carrier partners - including 18 of the top-20 food and beverage companies and nine of the top-10 CPG companies. The platform tracks over 1 million loads and $100 billion in freight at any given time. FourKites leverages data science breakthroughs and machine learning to provide real-time tracking of shipments across all modes of transportation in 80+ countries, and calculates the industry’s most accurate ETAs. In 2020, FourKites expanded visibility into the yard, creating a new category of software that gives enterprises the ability to proactively manage all their facilities based on real-time in-transit and in-yard freight data and analytics.

“We are happy to have FourKites as a global partner,” said Mark Mc Arthur, Managing Director of Alpega North America. “Their leadership in the real-time visibility platform and digital yard management space will add tangible value to our customer’s businesses. We look forward to working with them.”

About FourKites
FourKites is the largest predictive supply chain visibility platform, delivering real-time visibility and predictive analytics for the broadest network of Global 1000 companies and third-party logistics firms. With the largest repository of supply chain data on the planet, FourKites’ network spans millions of GPS/ELD devices. Using a proprietary algorithm to calculate shipment arrival times, FourKites enables customers to lower operating costs, improve on-time performance and strengthen end-customer relationships. The platform is optimized for mobile devices and equipped with market-leading end-to-end security. For more information, visit http://www.fourkites.com .

About Alpega
Alpega is a global provider of cloud-based transportation management systems (TMS). Alpega enables shippers, their customers, logistics service providers and carriers the ability to collaboratively manage end-2-end transportation activities for increased visibility, capacity and reduced freight spend. By streamlining transportation sourcing, planning, execution, settlement and analytics, Alpega solutions transform local and global supply chains into collaborative ecosystems - bringing transparency and efficiency to all trading partners involved. Alpega’s 200,000+ user community are present in 80 countries worldwide. For more information, visit na.alpegagroup.com for North America; and alpegagroup.com for Europe.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye